Inhibition of human cytochrome P-450 CYP1A2 by flavonoids: A quantitative structure-activity relationship study

Yaoxue Xuebao

Volumn 43, Issue 12, 2008, Pages 1198-1204

  Li, Jian Kang ^a   He, Fan ^a   Bi, Hui Chang ^a   Zuo, Zhong ^b   Liu, Bai Dong ^a   Luo, Hai Bin ^a   Huang, Min ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cytochrome P 450 CYP1A2; Drug design; Flavonoids; Inhibition; Quantitative structure activity relationship

Indexed keywords

CYP1A2 PROTEIN, HUMAN; CYTOCHROME P450 1A2; FLAVONOID;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; HUMAN; LIVER MICROSOME; METABOLISM; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

CYTOCHROME P-450 CYP1A2; FLAVONOIDS; HUMANS; MICROSOMES, LIVER; MODELS, MOLECULAR; MOLECULAR STRUCTURE; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 57749173672     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Faber MS, Jetter A, Fuhr U. Assessment of CYP1A2 activity in clinical practice: why, how, and when? [J]. Basic Clin Pharmacol Toxicol, 2005,97:125-134.
2. Butler MA, Iwasaki M, Guengerich FP, et al. Human cytochrome P-450PA (P450IA2), the phenacetin 0-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines [J]. Proc Natl Acad Sci USA, 1989,86: 7696-7700.
3. Eaton DL, Gallagher EP, Bammler TK, et al. Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity [J]. Pharmacogenetics, 1995,5:259-274.
4. Guengerich FP, Parikh A, Turesky RJ, et al. Inter-individual differences in the metabolism of environmental toxicants: cytochrome P450 1A2 as a prototype [J]. Mutat Res, 1999,428:115-124.
5. Song LH, Qin XP, Dai WM. The relation between cytochrome P4501A2 and malignant tumors [J]. J Shanxi Coll Tradit Chin Med, 2000,1: 26-28.
6. Wang CY, Wu HK, Yu CQ, et al. Research advance of flavonoids [J]. J Heilongjiang August First Land Reclamation Univ, 2007, 19:75-78.
7. Huang HY, Zha XL. Development in research of antitumor effect of flavones compounds [J]. Chin J New Drugs Clin Rem, 2002,21: 428-433.
8. Heim KE, Tagliaferro AR, Bobilya DJ. Flavonoid antioxidants: chemistry, metabolism and structure-activity relationships [J]. J Nutr Biochem, 2002,13:572-584.
9. Lin YM, Zhou Y, Flavin MT, et al. Chalcones and flavonoids as anti-tuberculosis agents [J]. Bioorg Med Chem, 2002,10:2795-2802.
10. Lin YM, Flavin MT, Cassidy CS, et al. Biflavonoids as novel antituberculosis agents [J]. Bioorg Med Chem Lett, 2001,11:2101-2104.
11. Birt DF, Hendrich S, Wang W. Dietary agents in cancer prevention: flavonoids and isoflavonoids [J]. Pharmacol Ther, 2001,90:157-177.
12. Moon YJ, Wang X, Morris ME. Dietary flavonoids: effects on xenobiotic and carcinogen metabolism [J]. Toxicol In Vitro, 2006,20:187-210.
13. Zhou S, Gao Y, Jiang W, et al. Interactions of herbs with cytochrome P450 [J]. Drug Metab Rev, 2003,35: 35-98.
14. Sesardic D, Boobis AR, Murray BP, et al. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man [J]. Br J Clin Pharmacol, 1990,29:651-663.
15. Cho US, Park EY, Dong MS, et al. Tight-binding inhibition by alpha-naphthoflavone of human cytochrome P450 1A2 [J]. Biochim Biophys Acta, 2003,1648; 195-202.
16. Ekins S, de Groot MJ, Jones JP. Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites [J]. Drug Metab Dispos, 2001,29:936-944.
17. Akamatsu M. Current state and perspectives of 3D-QSAR [J]. Curr Top Med Chem, 2002,2:1381-1394.
18. Kim KH, Greco G, Novellino EA. Critical review of recent CoMFA applications: Vol 12-14 [M/OL]. Amsterdam; Springer Netherlands Press, 1998:257-315 [2008-07-07]. http://www.springerlink.com/content/r06273516671w130.
19. Korhonen LE, Rahnasto M, Mahonen NJ, et al. Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors [J]. J Med Chem, 2005,48:3808-3815.
20. He F, Bi HC, Xie ZY, et al. Rapid determination of six metabolites from multiple cytochrome P450 probe substrates in human liver microsome by liquid chromatography/mass spectrometry: application to high-throughput inhibition screening of terpenoids [J]. Rapid Commun Mass Spectrom, 2007,21:635-643.
21. ow [J]. J Chromatogr B, 2007,847:245-261.
22. Luo HB, Cheng CQ, Cheng YK. Complex retention behavior of pyrimidines on biomembrane-mimic immobilized-artificial-membrane phase [J]. J Chromatogr B, 2007,853:114-122.
23. Golbraikh A, Tropsha A. Beware of q2! [J]. J Mol Graph Model, 2002,20:269-276.